Your browser doesn't support javascript.
Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients
Ilies Benotmane; Gabriela Gautier-Vargas; Noelle Cognard; Jerome Olagne; Francoise Heibel; Laura Braun Parvez; Jonas Martzloff; Peggy Perrin; Bruno Moulin; Samira Fafi-Kremer; Sophie Caillard.
  • Ilies Benotmane; Service de nephrologie et transplantation, Hopitaux universitaires de Strasbourg
  • Gabriela Gautier-Vargas; service de nephrologie et transplantation, hopitaux universitaires de strasbourg
  • Noelle Cognard; service de nephrologie et transplantation, hopitaux universitaires de strasbourg
  • Jerome Olagne; service de nephrologie et transplantation, hopitaux universitaires de strasbourg
  • Francoise Heibel; service de nephrologie et transplantation, hopitaux universitaires de strasbourg
  • Laura Braun Parvez; service de nephrologie et transplantation, hopitaux universitaires de strasbourg
  • Jonas Martzloff; service de nephrologie et transplantation, hopitaux universitaires de strasbourg
  • Peggy Perrin; service de nephrologie et transplantation, hopitaux universitaires de strasbourg
  • Bruno Moulin; service de nephrologie et transplantation, hopitaux universitaires de strasbourg
  • Samira Fafi-Kremer; service de virologie, hopitaux universitaires de strasbourg
  • Sophie Caillard; service de nephrologie et transplantation, hopitaux universitaires de strasbourg
Preprint Dans Anglais | medRxiv | ID: ppmedrxiv-21252741
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
Data concerning the anti-SARS-CoV-2 antibody response after mRNA COVID-19 vaccine in kidney transplant recipients (KTRs) are currently lacking. Here, we sought to examine this issue by analyzing the serological response observed in 241 KTRs after a first vaccine injection. Our results indicate that KTRs have a weak anti-SARS-CoV-2 antibody response, ultimately resulting in a low seroconversion rate (26/241, 10.8%). This phenomenon likely stems from a high immunosuppression burden in this clinical population.
Texte intégral: Disponible Collection: Preprints Base de données: medRxiv Les sujets: Vaccins langue: Anglais Année: 2021 Type de document: Preprint
Texte intégral: Disponible Collection: Preprints Base de données: medRxiv Les sujets: Vaccins langue: Anglais Année: 2021 Type de document: Preprint